Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy
Hyung‐Don Kim, Jinho Shin, In Hye Song, Jaewon Hyung, Hyungeun Lee, Min‐Hee Ryu, Young Soo Park
Topics & Concepts
ConcordanceMedicineInternal medicineNivolumabConcordance correlation coefficientCancerOncologyChemotherapyGastroenterologyImmunotherapyMathematicsStatisticsCancer Immunotherapy and BiomarkersGastric Cancer Management and OutcomesInflammatory Biomarkers in Disease Prognosis